Family Spillover Effects of Healthcare Treatments
In a recent post on the IVI-sponsored Health Affairs featured blog series, Anupam Jena and IVI Strategic Advisory Panel member, Sachin Kamal-Bahl, examine the spillover effects of healthcare for patients’ families. These family spillover benefits, they argue, may be significant. For example, a parent of a blind child would likely be willing to pay far more […]
21st Century Cures Act and Lowered Confidence in FDA-Approved Drugs and Devices
In a recent post on the IVI-sponsored Health Affairs featured blog series, Deborah Mazer and Gregory Curfman focus on provisions of the 21st Century Cures Act that will impact the FDA’s oversight of approved drugs and medical devices, including subtle changes to the approval procedures and a provision that permits-off label promotion of health care economic […]
Employers Can Take a Larger Role in Controlling Drug Costs
In a recent post on the IVI-sponsored Health Affairs featured blog series, Robert Galvin and Troyen Brennan make the case for employers and pharmacy benefit managers to challenge drug manufacturers’ pricing models as a means of keeping costs in check, particularly in regard to launch prices. They suggest a strategy in which employers and pharmacy benefit […]
Analyzing the Promise, Challenges and Limitations of the Precision Medicine Initiative and Cancer Moonshot
In a recent post on the IVI-sponsored Health Affairs featured blog series, Jonathan Darrow, Aaron Kesselheim, and Jessica Lasky-Su outline the goals and promise of the Precision Medicine Initiative and Cancer Moonshot. Although they also outline some of the key challenges and limitations, the authors recognize that there is a significant opportunity to translate the advances […]
Examining Value Frameworks and Key Considerations for Improvement
In a recent post on the IVI-sponsored Health Affairs featured blog series, the National Pharmaceutical Council’s Robert Dubois (also member of IVI Strategic Advisory Panel) and Kimberly Westrich examine current value assessment models’ readiness for use in healthcare decision-making. Applying NPC’s 35 Guiding Practices, they conclude that all existing frameworks possess individual strengths and weaknesses, but […]
Examining the Links Between R&D Costs and Drug Prices
In a recent post on the IVI-sponsored Health Affairs featured blog series, Peter Bach, Zachary Helms, and Nancy Yu leverage public data to estimate both the premiums that companies earn and the amount they spend on research, challenging pharmaceutical companies’ claims regarding R&D spending. Read the full article here. About the Health Affairs/IVI Featured Blog Series: Drugs […]
Explaining the “Patent Dance” for Biosimilars and the Importance of Trade Secrets
In a recent post on the IVI-sponsored Health Affairs featured blog series, Claire Laporte explains why the patent process dispute between biosimilar and branded drug manufacturers is headed all the way to the Supreme Court and why the outcome could influence intellectual property laws and protections for trade secrets. Read the full article here. About the Health […]
Discussion on “Wisdom Study” CED Model
In a recent post on the IVI-sponsored Health Affairs featured blog series, Sarah Rosenberg-Wohl and coauthors discuss the potential of private insurer funding for CER through “Coverage with Evidence Development,” using the Wisdom Study as a real-world case study. Read the full article here. About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership […]
Accelerated Approval for New Drugs and a Conditional Approval Option
In a recent post on the IVI-sponsored Health Affairs featured blog series, Robert Bohrer addresses the current system in place for the accelerated approval of novel drugs and notes the delicate issues that regulators are confronted with. Bohrer suggests that a new “conditional approval” approach may be the best compromise and provide a way forward. Read […]
The OPEN ACT as a Pathway to Accelerated Drug Development
In a recent post on the IVI-sponsored Health Affairs featured blog series, Max Bronstein, Emil Kakkis, David Fajgenbaum, and Chip Chambers address the current landscape of drug development, making the case for the OPEN ACT (Orphan Product Extensions Now, Accelerating Cures and Treatments), new legislation that would extend the exclusivity period for any drug repurposed for […]